HGH-Fragment 176-191 Calculator

What Is HGH Fragment 176-191?

HGH Fragment 176-191 is a synthetic peptide composed of 16 amino acids that reproduces the C-terminal region of human growth hormone (somatropin). The intact growth hormone molecule contains 191 amino acids, and research conducted in the 1990s identified that the hormone's fat-burning properties are concentrated in a well-defined stretch spanning amino acids 176 through 191. This specific segment was isolated, synthetically reproduced, and stabilized for research purposes. The "176-191" designation therefore points directly to the position of this sequence within the full hormone molecule.

The central idea behind this fragment is functional separation. Whereas intact growth hormone exerts a wide range of effects on the organism — including growth, tissue building, and a marked rise in IGF-1 — HGH Fragment 176-191 isolates only the lipolytic (fat-mobilizing) portion. In preclinical models, the fragment was shown to stimulate fat breakdown without triggering the growth-promoting and glucose-related effects characteristic of full growth hormone to the same degree. For this reason, HGH Fragment 176-191 is frequently described in research as the "lipolytic fragment" of growth hormone.

HGH Fragment 176-191 is closely related to AOD-9604, another derivative of the same C-terminal region. AOD-9604 is a modified variant in which an additional tyrosine residue improves stability, and both compounds are discussed within the same metabolic research context. Importantly, the fragment is not a secretagogue: it does not stimulate the body's own release of growth hormone but acts directly on fat cells. This sets it apart fundamentally from GHRH analogs and ghrelin mimetics, which work through the pituitary. All information presented here relates strictly to the research context.

Mechanisms of Action

HGH Fragment 176-191 exerts its effects primarily by influencing fat metabolism in adipocytes (fat cells). The mechanisms investigated in research can be summarized as follows:

• Stimulation of lipolysis: The fragment promotes the breakdown of triglycerides stored in fat cells into free fatty acids and glycerol. This process makes stored energy available for further metabolism and forms the core of the peptide's lipolytic activity.
• Inhibition of lipogenesis: Alongside promoting fat breakdown, the fragment reduces the formation of new fat tissue in preclinical models by dampening the conversion of dietary components into new fat stores. The combined effect of increased breakdown and reduced buildup shifts the balance of fat metabolism.
• Increased fat oxidation: Beyond simply releasing fatty acids, animal models suggest the fragment increases the actual burning of those fatty acids for energy. This is important, because released fatty acids could otherwise be re-stored in fat cells if not followed by oxidation.
• No relevant rise in IGF-1: Unlike intact growth hormone, the fragment does not produce a pronounced increase in insulin-like growth factor 1 (IGF-1) in the research literature. As a result, the growth-promoting effects associated with IGF-1 are largely absent, which is considered a key distinction from the full hormone.
• Limited effect on blood glucose: Full growth hormone can impair insulin sensitivity and raise blood sugar. HGH Fragment 176-191 showed a markedly smaller influence on glucose metabolism in preclinical studies, because the diabetogenic portion of the hormone lies outside the 176-191 sequence.
• No action through the growth axis: The fragment does not bind the classical growth hormone receptor in a way that drives tissue growth, and it does not stimulate the pituitary. Its activity remains focused on fat metabolism, which explains its relatively narrow profile.

In summary, HGH Fragment 176-191 is intended to decouple the fat-mobilizing properties of growth hormone from its growth-related and metabolic side effects. Whether this theoretical profile holds up in robust human clinical data remains the subject of ongoing research.

Dosage Calculation

HGH Fragment 176-191 is dosed in micrograms (mcg) in the research context. Because the peptide has a short half-life, many protocols use a divided daily dose. Slow titration is generally not required, though starting at the lower end of the range is a reasonable precaution.

Standard Dosing Parameters

• Conservative dose: 100 mcg (0.10 mg) per injection
• Standard dose: 250 mcg (0.25 mg) per injection
• Higher range: 400–500 mcg (0.40–0.50 mg) per injection
• Frequency: Once or twice daily, with many protocols dosing in a fasted state in the morning and optionally before physical activity
• Half-life: Approximately 2.5 hours, which explains the common practice of splitting the daily amount into several smaller doses
• Typical syringe: 0.3 mL insulin syringe (29–31 gauge, 6–8 mm needle)

Example Calculation: 10 mg Vial with 2 mL BAC Water

A common vial size for HGH Fragment 176-191 is 10 mg. Adding 2 mL of bacteriostatic water gives a concentration of 5 mg/mL (5,000 mcg/mL).

• 100 mcg dose: 100 ÷ 5000 = 0.02 mL (2 units on a U100 syringe)
• 250 mcg dose: 250 ÷ 5000 = 0.05 mL (5 units)
• 400 mcg dose: 400 ÷ 5000 = 0.08 mL (8 units)
• 500 mcg dose: 500 ÷ 5000 = 0.10 mL (10 units)

At 250 mcg once daily, a 10 mg vial provides 40 days of dosing; at two 250 mcg doses per day, it lasts 20 days. Because small volumes are especially error-prone here, precise calculation is worthwhile. Use the HGH Fragment 176-191 calculator above to determine accurate volumes for any vial size, reconstitution volume, and target dose.

Injection Site and Timing Selection

HGH Fragment 176-191 is typically injected subcutaneously into the abdominal fat layer. Because the lipolytic effect is mediated systemically, targeting a specific fat depot with the injection is not necessary, and localized injection does not produce spot reduction of fat. Many research protocols time administration to a fasted state — for example, in the morning before the first meal — since a low insulin level favors lipolysis. Rotating injection sites reduces local irritation.

Reconstitution

HGH Fragment 176-191 is supplied as a lyophilized (freeze-dried) powder in sealed vials. It must be reconstituted with bacteriostatic water (BAC water) before use. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection is less suitable for multi-dose vials because it contains no preservative.

Step-by-Step Reconstitution Protocol

1. Gather supplies: the HGH Fragment 176-191 vial, a vial of bacteriostatic water, alcohol swabs, a sterile draw needle (18–21 gauge), and your insulin syringe for injection.
2. Wipe the rubber septa of both vials with fresh alcohol swabs and allow them to air-dry for about 30 seconds. Do not touch or blow on the septa afterward.
3. Draw the desired volume of BAC water into the draw syringe. For a 10 mg vial, 2 mL is a common starting point that simplifies dose calculation.
4. Insert the needle into the peptide vial at an angle, directing the tip toward the inner glass wall rather than the powder cake. A direct stream of water onto the lyophilized powder can mechanically stress the delicate peptide bonds.
5. Slowly push the plunger so the BAC water runs down the inner glass wall and gently wets the powder from below.
6. Gently roll or swirl the vial between your palms until the powder is completely dissolved. The finished solution should appear clear and colorless. Do not shake or vortex the vial.
7. Label the vial with the reconstitution date and concentration, for example "HGH Fragment 176-191 5 mg/mL — reconstituted [date]".

If the solution appears cloudy, discolored, or contains visible particulate matter, the vial should be discarded and not used.

Storage and Shelf Life

• Lyophilized powder (unreconstituted): Store at −20°C for long-term storage, where the powder remains stable for many months. Short-term storage at 2–8°C in a refrigerator is acceptable. Protect from light and moisture, and do not leave at room temperature for extended periods.
• Reconstituted solution: Store in the refrigerator at 2–8°C and use within approximately 28–30 days. Keep the vial upright and away from light. Write the reconstitution date prominently on the label and discard the vial once the window has elapsed, regardless of remaining volume.
• Do not freeze reconstituted peptide. Freeze-thaw cycles cause protein aggregation and a loss of biological activity. Once reconstituted, the vial must remain refrigerated throughout its use window.
• Transport: Use an insulated cooler with an ice pack for any travel lasting more than one to two hours. Commercial insulated medication pouches maintain 2–8°C for 24–48 hours. Avoid exposure to temperatures above 25°C during transport.

Side Effects and Safety Profile

HGH Fragment 176-191 is described in preclinical research as generally well tolerated, particularly because of its narrower profile compared with full growth hormone. Since human clinical data is limited, all use remains in the research domain, and a definitive safety verdict is not possible.

Commonly Reported Observations

• Mild redness, transient swelling, or brief discomfort at the injection site. These local reactions usually resolve within a few hours, and rotating injection sites reduces irritation.
• Temporary fatigue or a sensation of hunger, which some users report with fasted use and which is associated with the mobilization of energy reserves.
• An occasional flushing sensation or mild lightheadedness shortly after injection, which typically subsides quickly.

Less Common or Theoretical Concerns

• Effect on blood glucose: Although the fragment is expected to influence glucose metabolism far less than full growth hormone, complete neutrality is not guaranteed. Individuals with impaired glucose metabolism should take this into account.
• Allergic reactions: As with any injectable peptide, hypersensitivity reactions to the active compound or to the benzyl alcohol in BAC water are theoretically possible.
• Limited long-term data: No extensive long-term human studies are available. The effects of sustained use over long periods are not adequately characterized.

Contraindications

• Pregnancy and breastfeeding, due to a lack of robust safety data
• Known hypersensitivity to the peptide or any component of the preparation
• Active cancer without medical supervision

No serious adverse events specifically attributable to HGH Fragment 176-191 have been described in the available literature at standard research doses. Given the absence of large-scale human studies, caution is warranted, and consultation with a qualified healthcare professional is strongly recommended.

Combinations and Stacks

HGH Fragment 176-191 and AOD-9604

Because AOD-9604 is a closely related, stabilized variant of the same C-terminal region, the two compounds are generally regarded in research as alternatives rather than a stack to be used simultaneously. Those who want to examine the metabolic research question from two angles compare the profiles of the two fragments rather than combining them.

HGH Fragment 176-191 and GH Secretagogues

In practice, the fragment is frequently discussed in connection with peptides of the growth hormone axis. Secretagogues such as Ipamorelin or GHRH analogs such as CJC-1295 without DAC work through the body's own release of growth hormone, and therefore through a fundamentally different mechanism than the fragment, which acts directly on fat cells. The conceptual appeal of this combination lies in its complementarity: one element targets the hormone level, the other targets fat metabolism itself. Dosing details for these peptides are available in their respective calculators.

HGH Fragment 176-191 and Tesamorelin

Tesamorelin is a GHRH analog discussed in research specifically in connection with visceral fat tissue. Because Tesamorelin works through the growth hormone axis while the fragment acts directly through lipolysis, the two compounds address different levels of fat metabolism. The relevant parameters can be reviewed using the Tesamorelin calculator.

Frequently Asked Questions

How does HGH Fragment 176-191 differ from real growth hormone?

Real growth hormone is a complete 191-amino-acid protein with a broad range of effects, including growth, tissue building, and a marked rise in IGF-1. HGH Fragment 176-191, by contrast, reproduces only the C-terminal region in which the fat-mobilizing activity is located. The fragment is therefore intended to stimulate lipolysis without triggering the growth-promoting and glucose-related effects of the full hormone to the same extent.

Does the fragment raise IGF-1 levels?

According to the available preclinical literature, HGH Fragment 176-191 does not produce a pronounced increase in IGF-1. This property is considered a central distinguishing feature compared with intact growth hormone, since the hormone's growth-promoting effects are largely mediated through IGF-1.

Is the fragment a GH secretagogue?

No. A secretagogue stimulates the pituitary to release more of the body's own growth hormone. HGH Fragment 176-191 works differently: it acts directly on fat metabolism in the adipocytes and does not stimulate the pituitary. This sets it apart fundamentally from peptides such as Ipamorelin or GHRH analogs.

Why is the fragment often used in a fasted state?

A low insulin level favors lipolysis, while an elevated insulin level dampens fat mobilization. For this reason, many research protocols time administration to a fasted state — for example, in the morning before the first meal or before physical activity — so that the fat-mobilizing effect is not blunted by a concurrent meal.

Does injecting into a specific body area cause local fat loss?

No. The effect of HGH Fragment 176-191 is mediated systemically. Injecting into the abdomen or another region does not produce targeted breakdown of fat tissue at that site. The choice of injection site is therefore based on practical considerations rather than a desire for a localized effect.

How do HGH Fragment 176-191 and AOD-9604 differ?

Both compounds are derived from the same C-terminal region of growth hormone. AOD-9604 is a modified variant in which an additional tyrosine residue improves the stability of the sequence. HGH Fragment 176-191, by contrast, corresponds to the unmodified fragment sequence. In research, both are considered within the same metabolic context and are usually compared as alternatives.

Why is the fragment often dosed several times per day?

The half-life of HGH Fragment 176-191 is approximately 2.5 hours, so the peptide is cleared from the circulation relatively quickly. To achieve more even exposure across the day, many protocols split the daily amount into one or two smaller doses rather than administering it in a single dose.

Where can I buy HGH Fragment 176-191?

Medical Disclaimer: The information on this page is provided for educational and research purposes only. HGH Fragment 176-191 is not an approved drug or medical treatment and is sold strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.